Iridex Corp (IRIX) Stock Price
IRIXStock
$0.81−22.42%52W
Market Cap$14.31M
P/E—
PEG Ratio0.94
Div yield—
Beta0.62
IRIX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-30.82%
Price vs S&P 500 (4W)28.01%
PEG Ratio0.94
VGM Score47.94
IRIX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.01 | -$0.07 | -568.00%(-$0.06) | |
| Q1 2026 | -$0.07 | -$0.03 | +57.14%(+$0.04) | |
| Q4 2025 | -$0.02 | $0.00 | +104.00%(+$0.02) | |
| Q3 2025 | — | -$0.09 | — |
IRIX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
IRIXIridex Corp | B | D | D | 0.3x | 7.7% | 35.9% | -5.4% | $0.81 |
| MDTMedtronic plc | B | C | B | 3.2x | 3.8% | 65.7% | 18.1% | $94.75 |
| ITGRInteger Holdings Corporation | C | C | A | 2.3x | 11.6% | 26.1% | 9.7% | $126.70 |
| LIVNLivaNova PLC Ordinary Shares | C | B | B | 2.9x | 8.2% | 68.1% | 12.5% | $77.58 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | D | 3.7x | 88.2% | 58.7% | 12.2% | $70.78 |
| AXGNAxogen, Inc. Common Stock | F | B | B | 8.1x | 14.9% | 74.6% | -11.8% | $34.62 |
| BLFSBioLife Solutions Inc. | F | C | A | 18.4x | 14.9% | 63.9% | 2.9% | $38.61 |
| CNMDCONMED Corporation | B | C | B | 1.0x | 9.8% | 55.8% | 8.0% | $46.72 |
| CBLLCeriBell, Inc. Common Stock | F | A | A | 9.4x | — | 88.9% | -68.6% | $25.04 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | 2.2x | 12.4% | 76.5% | 18.5% | $14.16 |
| CVCapsoVision, Inc. Common Stock | F | D | B | 25.0x | — | 50.9% | -217.1% | $6.53 |
About Iridex Corp
IRIDEX manufactures laser-based medical systems for ophthalmology, powered by proprietary Micropulse technology that provides competitive differentiation. The company generates revenue through sales of surgical consoles, delivery devices, glaucoma treatment systems, consumables, and support services, with additional exposure to veterinary and ENT markets. IRIDEX operates globally with primary revenue contributions from North America, Europe, and Asia/Pacific.